TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21417535

Group type: EXPERIMENTAL
Intervention: Immediate cognitive-behavioral therapy (CBT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Delayed cognitive-behavioral therapy (CBT)
Number of subjects: 134
Study: 18332407

Group type: EXPERIMENTAL
Intervention: Chronic illness management initiative involving joint formulation of comprehensive individual patient care plans
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Chronic illness management initiative
Number of subjects: 33
Study: 16520665

Group type: EXPERIMENTAL
Intervention: Sunitinib malate (SU11248) 50 mg after a high-fat, high-calorie meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sunitinib malate (SU11248) 50 mg after a 10-h fast
Number of subjects: 16
Study: 12920408

Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/d
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg/d
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clozapine 600 mg/d
Number of subjects: 39

Group type: COMPARATOR
Intervention: Haloperidol (4-week trial)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Other antipsychotics and low doses of antiparkinsonians
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Norclozapine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 39
Study: 10914361

Group type: EXPERIMENTAL
Intervention: Rate adaptive atrial pacing therapy
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: DDDR pacing postablation
Number of subjects: 97

Group type: COMPARATOR
Intervention: VDD pacing postablation
Number of subjects: 97

Group type: COMPARATOR
Intervention: No atrial pacing therapy
Number of subjects: 97
Study: 9006183

Group type: EXPERIMENTAL
Intervention: Gentle teaching
Number of subjects: 24

Group type: COMPARATOR
Intervention: Behaviour modification
Number of subjects: 24
Study: 1319601

Group type: EXPERIMENTAL
Intervention: Smoked marijuana
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 21

Group type: COMPARATOR
Intervention: Smoked marijuana and Oral THC
Number of subjects: 21
Study: 6478738

Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg + Methadone 100% of maintenance dose
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diazepam 40 mg + Methadone 150% of maintenance dose
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Methadone 100% of maintenance dose
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Methadone 150% of maintenance dose
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Methadone 200% of maintenance dose
Number of subjects: 5
Study: 30734266

Group type: EXPERIMENTAL
Intervention: mirikizumab 30 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: mirikizumab 100 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: mirikizumab 300 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 204
Study: 30397355

Group type: EXPERIMENTAL
Intervention: 4-month regimens
Number of subjects: 3405

Group type: EXPERIMENTAL
Intervention: High smear grades and cavitation
Number of subjects: 3405

Group type: EXPERIMENTAL
Intervention: Adherence of ≤90%
Number of subjects: 3405

Group type: EXPERIMENTAL
Intervention: Baseline smear grade of 3+
Number of subjects: 3405

Group type: EXPERIMENTAL
Intervention: HIV seropositivity
Number of subjects: 3405
Study: 25786826

Group type: EXPERIMENTAL
Intervention: Tourniquet (A) group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-tourniquet (B) group
Number of subjects: 84
Study: 24521993

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (1400 mg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2)
Number of subjects: 127
Study: 21720426

Group type: EXPERIMENTAL
Intervention: Full subsidy (8 weight loss counseling visits and 2 meals per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Partial subsidy (8 weight loss counseling visits and 1 meal per day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Full subsidy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Partial subsidy
Number of subjects: 50
Study: 20581167

Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy with bronchoalveolar lavage (FO-BAL) plus noninvasive tests (n = 113)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Noninvasive tests only (n = 106)
Number of subjects: 219
Study: 17869596

Group type: EXPERIMENTAL
Intervention: Levobupivacaine infusion (16.25mg/h for 24h)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 15812806

Group type: COMPARATOR
Intervention: Normal renal arteries
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Renal artery fibromuscular dysplasia (FMD)
Number of subjects: 35
Study: 11448018

Group type: EXPERIMENTAL
Intervention: 66 mg/day etidronate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 133 mg/day etidronate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 200 mg/day etidronate
Number of subjects: 80

Group type: COMPARATOR
Intervention: No etidronate (Control Group A)
Number of subjects: 80
Study: 9746768

Group type: EXPERIMENTAL
Intervention: Tacrolimus/methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine/methotrexate
Number of subjects: 0
Study: 8040990

Group type: EXPERIMENTAL
Intervention: 99mTc MIBI injection during stress testing
Number of subjects: 16
Study: 3181147

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 180

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 180

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 180
Study: 31112070

Group type: EXPERIMENTAL
Intervention: Static images of different lifting techniques
Number of subjects: 18
Study: 28779921

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 83
Study: 24828371

Group type: EXPERIMENTAL
Intervention: Hematogram model for predicting future MetS in elderly men
Number of subjects: 4539

Group type: EXPERIMENTAL
Intervention: Hematogram model for predicting future MetS in elderly women
Number of subjects: 4539
Study: 23383690

Group type: EXPERIMENTAL
Intervention: Acute resistance training (RT) session
Number of subjects: 24
Study: 21912466

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endomicroscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diagnostic procedure (four biopsies every 10 cm)
Number of subjects: 0
Study: 19506112

Group type: EXPERIMENTAL
Intervention: DITPA
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17709433

Group type: EXPERIMENTAL
Intervention: Refined olive oil (50 g/m² body surface area)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-palmitic sunflower oil (50 g/m² body surface area)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Butter (50 g/m² body surface area)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mixture of vegetable and fish oils (50 g/m² body surface area)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Postprandial TRL at 3 h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Postprandial TRL at 5 h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Postprandial TRL
Number of subjects: 14
Study: 15018874

Group type: EXPERIMENTAL
Intervention: Dual chamber ICD (DDED)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Single chamber ICD (SC)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Composite primary endpoint includes: all-cause mortality, invasive intervention, hospitalization due to cardiovascular cause, inappropriate shocks, sustained symptomatic atrial tachyarrhythmias requiring urgent termination or lasting more than 48h.
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Secondary endpoints include individual components of CSAE, cardiovascular status, quality of life, and analysis of atrial and ventricular arrhythmias.
Number of subjects: 343
Study: 11485526

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (GBP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Open gastric bypass (GBP)
Number of subjects: 70
Study: 9724277

Group type: EXPERIMENTAL
Intervention: hNPY 14.3 pmol . kg‐1 . min‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: hNPY 1.4 pmol . kg‐1 . min‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no hNPY)
Number of subjects: 12
Study: 7805426

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid (500 mg three times daily)
Number of subjects: 76
Study: 3199275

Group type: EXPERIMENTAL
Intervention: Glucose/glycine/glycylglycine-based ORS
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard WHO/ORS
Number of subjects: 62
Study: 30333054

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 940

Group type: COMPARATOR
Intervention: Conversion to IUI
Number of subjects: 940
Study: 28375706

Group type: EXPERIMENTAL
Intervention: Diabetes without metformin treatment
Number of subjects: 8381

Group type: EXPERIMENTAL
Intervention: Diabetes with metformin treatment
Number of subjects: 8381

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 8381

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 8381
Study: 25442801

Group type: EXPERIMENTAL
Intervention: CT density distribution kurtosis (iKurtosis)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CT density distribution skewness (iSkewness)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Log-iKurtosis
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Log-iSkewness
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Radiologic scores (RS1 and RS2)
Number of subjects: 26
Study: 23147718

Group type: EXPERIMENTAL
Intervention: Triage group (full screening plus option of personalized phone triage)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Minimal screening group (Distress Thermometer plus usual care)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Triage group
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Full screening group (Distress Thermometer, CPC, Pain Thermometer, Fatigue Thermometer, Psychological Screen for Cancer Part C)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Referrals
Number of subjects: 549
Study: 21896815

Group type: EXPERIMENTAL
Intervention: Intensive latrine promotion
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control (no latrine promotion)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Latrine promotion vs Control
Number of subjects: 320
Study: 19846406

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 39

Group type: COMPARATOR
Intervention: LMA-Unique (LMA-U)
Number of subjects: 39
Study: 16924356

Group type: EXPERIMENTAL
Intervention: Clingfilm covering during phototherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: No clingfilm covering during phototherapy
Number of subjects: 106
Study: 15153664

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg once daily for 12 weeks
Number of subjects: 6
Study: 11286302

Group type: EXPERIMENTAL
Intervention: Oral trimetazidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 0
Study: 8900987

Group type: EXPERIMENTAL
Intervention: Inflated G-suit (50 mm Hg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Non-inflated G-suit
Number of subjects: 1

Group type: COMPARATOR
Intervention: Without G-suit
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group (non-diabetic subjects)
Number of subjects: 1
Study: 2108511

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 85871

Group type: EXPERIMENTAL
Intervention: Selenomethionine isotope scanning
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 46
Study: 31489410

Group type: EXPERIMENTAL
Intervention: 1% NaOCl with ultrasound devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 0
Study: 28650087

Group type: EXPERIMENTAL
Intervention: Oral health educational strategy (OHES) and Atraumatic Restorative Treatment (ART) restoration
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral health educational strategy (OHES)
Number of subjects: 72
Study: 25866155

Group type: EXPERIMENTAL
Intervention: 5 g of Lentinula edodes (shiitake) mushrooms daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 10 g of Lentinula edodes (shiitake) mushrooms daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lentinula edodes (shiitake) mushrooms consumption
Number of subjects: 52
Study: 24525232

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (methotrexate, vinblastine, doxorubicin, cisplatin)
Number of subjects: 0
Study: 22774398

Group type: EXPERIMENTAL
Intervention: Thermal balneotherapy with ozonized water
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-mineral water bath (control)
Number of subjects: 30
Study: 20573380

Group type: EXPERIMENTAL
Intervention: TUNEL assay
Number of subjects: 194
Study: 18052593

Group type: EXPERIMENTAL
Intervention: eEVAR (n=18)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Open repair (n=31)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Mixed prospective group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Historical open repair group
Number of subjects: 49
Study: 16287407

Group type: EXPERIMENTAL
Intervention: Optimistic message weight loss program
Number of subjects: 349

Group type: COMPARATOR
Intervention: Balanced message weight loss program
Number of subjects: 349
Study: 12163798

Group type: EXPERIMENTAL
Intervention: Candidemic septic shock
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bacteremic septic shock
Number of subjects: 10
Study: 10394686

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine 3 mg + Piracetam 1.6 g every 12 hours for 90 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine 1.5 mg + Piracetam 0.8 g every 8 hours for 90 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine-Piracetam (D-P)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine 1.5 mg + Piracetam 0.8 g every 8 hours
Number of subjects: 50
Study: 8785138

Group type: EXPERIMENTAL
Intervention: Cis-atracurium 0.18 mg kg‐1 h‐1 (group 1, n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1 h‐1 (group 2, n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cis-atracurium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 12
Study: 1645087

Group type: EXPERIMENTAL
Intervention: Low tar, low nicotine cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low tar, middle nicotine cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Middle tar, middle nicotine cigarettes
Number of subjects: 0
Study: 6149589

Group type: EXPERIMENTAL
Intervention: Smoked marijuana (1 g cigarette containing 1.83% delta 9-THC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Delta 9-THC (17.5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nabilone (2 mg orally)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31498030

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 1077
Study: 29530271

Group type: COMPARATOR
Intervention: Levothyroxine (LT4) treatment; specific dosage and duration not mentioned.
Number of subjects: 150
Study: 27445468

Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: UMEC 62.5 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: VI 25 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: TIO 18 µg
Number of subjects: 0
Study: 24478226

Group type: EXPERIMENTAL
Intervention: Axxess stent
Number of subjects: 76

Group type: COMPARATOR
Intervention: Distal sirolimus‐eluting stents
Number of subjects: 76
Study: 22627912

Group type: EXPERIMENTAL
Intervention: Low-fat diets (65% or 55% carbohydrate)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: High-fat diets (45% or 35% carbohydrate)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Measured REE at 6 months
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Measured REE at 24 months
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 811
Study: 19117977

Group type: EXPERIMENTAL
Intervention: Hands-free, head-controlled pointer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Verbal guidance only
Number of subjects: 20
Study: 17253908

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 15996945

Group type: EXPERIMENTAL
Intervention: cladribine + prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: chlorambucil + prednisone
Number of subjects: 0
Study: 11993621

Group type: EXPERIMENTAL
Intervention: CREATINE (5 g of Cr, 4 times per day for 6 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLACEBO (same dosage of a glucose polymer)
Number of subjects: 12
Study: 9513799

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.6 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Morphine (16 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pentazocine (30 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 6
Study: 7710024

Group type: EXPERIMENTAL
Intervention: Nasal catheter with foam collar
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hudson mask
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nasal cannulae
Number of subjects: 11
Study: 2153355

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, 4 times daily for 4 months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 micrograms, 4 times daily for 4 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (4 times daily for 4 months)
Number of subjects: 25
Study: 351886

Group type: EXPERIMENTAL
Intervention: Cadaver donor pretreatment with 5 g of methylprednisolone and 7 g of cyclophosphamide
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonpretreated kidneys
Number of subjects: 52
Study: 30319049

Group type: EXPERIMENTAL
Intervention: Diabetic group (D)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Non-diabetic group (ND)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Diabetic group (D) with early recanalization
Number of subjects: 165

Group type: COMPARATOR
Intervention: Non-diabetic group (ND) with early recanalization
Number of subjects: 165

Group type: COMPARATOR
Intervention: Non-diabetic group (ND) without early recanalization
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Diabetic group (D) without early recanalization
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Complete recanalization at 24 h
Number of subjects: 165
Study: 27018511

Group type: EXPERIMENTAL
Intervention: Flexion group (knee flexed mildly < 30 degrees)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Extension group (knee fully extended)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups (leg elevated 25 cm for 72 hours)
Number of subjects: 108
Study: 25041383

Group type: EXPERIMENTAL
Intervention: Hydrogel patch applied directly on the affected area three times within the first 24 hours, followed by three additional patches over the next 3 days.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual care (adjustment of the denture's margins)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hydrogel patch
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual care (control lesions)
Number of subjects: 23
Study: 23865644

Group type: EXPERIMENTAL
Intervention: Pharmacy enrolled and delivered HIV risk reduction information to IDUs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacy only enrolled IDUs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacy did not engage IDUs
Number of subjects: 0
Study: 21757278

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (4 injections of 2 mL of 10% dextrose and 1 mL of 2% mepivacaine each 6 weeks apart)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (4 injections of 2 mL of saline solution and 1 mL of 2% mepivacaine each 6 weeks apart)
Number of subjects: 12
Study: 19840635

Group type: EXPERIMENTAL
Intervention: Final rinse with BioPure MTAD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intracanal medication with 2% chlorhexidine gel (CHX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Canal preparation with 1.3% NaOCl
Number of subjects: 30
Study: 16759839

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg every 8h
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bacteriostatic CFR
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bactericidal CFR
Number of subjects: 96
Study: 15373930

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody ATM-027
Number of subjects: 0
Study: 11769578

Group type: EXPERIMENTAL
Intervention: Group 1 (n = 41)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Group 2 (n = 16)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Group 3 (n = 19)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Group 4 (n = 30)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Group 5 (n = 14)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Group 6 (n = 10)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Group 7 (n = 6)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Group 1 and Group 3
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Blocking TSHRAb activity
Number of subjects: 136
Study: 9652559

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg infusion on day 0 and day 4)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 380
Study: 8115491

Group type: EXPERIMENTAL
Intervention: Veinotonyl 75
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42